Close Menu

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    Moderna begins Ebola vaccine trial amid DR Congo outbreak

    August 5, 2026

    Skye Africa Intelligence and ECSA-HC Sign Memorandum of Understanding to Scale AI-Enabled Health Solutions

    August 5, 2026

    Guatemala raises red alert as Fuego volcano erupts

    August 5, 2026
    Facebook X (Twitter) Instagram
    Mashreq DailyMashreq Daily
    • Automotive
    • Business
    • Entertainment
    • Health
    • Lifestyle
    • Luxury
    • News
    • Sports
    • Technology
    • Travel
    Mashreq DailyMashreq Daily
    Home » ZeptoMetrix Launches PROtrol: Quality Control Material for the Lateral Flow Immunoassay Market
    Featured News

    ZeptoMetrix Launches PROtrol: Quality Control Material for the Lateral Flow Immunoassay Market

    May 18, 2023
    Facebook Twitter Pinterest LinkedIn Tumblr Email

    BUFFALO, NY / ACCESSWIRE / May 16, 2023 / ZeptoMetrix® is excited to introduce PROtrol TM, a new line of products designed for antigen-based diagnostic methods. These third-party materials mimic a true clinical specimen and can be used to evaluate and monitor the performance of antigen-based assays, including lateral flow immunoassays for infectious diseases.

    ZeptoMetrix logo
    ZeptoMetrix logo

    PROtrol is the only whole organism reference material to provide complete testing data. Each lot of product is supplied with the protein concentration and TCID50 value, which minimizes qualification testing. PROtrol provides better reproducibility, which optimizes the use of financial spending and processing time through the decreased need for repeat testing.

    “The rapid expansion in development of antigen-based assays has highlighted some quality challenges. Inactivated, whole organism controls designed specifically for antigen tests can equip manufacturers with the tools they need to better evaluate the performance of their assays, leading to higher quality tests on the market,” said Dr. Karuna Sharma, Vice President & Chief Scientific Officer.

    PROtrol SARS-Related Coronavirus 2 (SARS-CoV-2) Isolate: USA-WA1/2020* is the first member of this product line (PROSARS(COV2)-587). As we move beyond the COVID-19 pandemic, ZeptoMetrix will continue to grow the PROtrol product line, providing high-quality controls to assay manufacturers seeking to expand access to inexpensive and easy-to-use diagnostics.

    “The launch and expansion of PROtrol enhances our position as the partner of choice for diagnostic test developers,” said Evangeline Gonzalez, President of Antylia Diagnostics division. “As we work with our diagnostic partners, ZeptoMetrix is pleased with the role that PROtrol plays to give patients around the world more access to diagnostic testing.”

    More information on how to order the new PROtrol and additional ZeptoMetrix products can be found at: https://www.zeptometrix.com

    About ZeptoMetrix®
    ZeptoMetrix® is an established industry leader in the design, development, and delivery of innovative, quality solutions to the infectious disease diagnostics market. Our expertise and abilities in molecular diagnostics, including external quality controls, verification panels, proficiency panels, customized and OEM products/services have set the industry standard for performance and reliability and make ZeptoMetrix the preferred choice for independent third-party quality control materials.

    Links:
    * (PROSARS(COV2)-587): product page
    https://www.zeptometrix.com/products/protrolt-sars-cov-2-isolate-usa-wa1-2020-1-ml

    Contact Information

    Andrew Zenger
    Global Product Manager
    andrew.zenger@antylia.com
    (716) 715-7417

    Related Files

    PROSARS(COV2)-587 Product Insert.pdf
    ZeptoMetrix Launches PROtrol.pdf

    SOURCE: ZeptoMetrix

    .

    ZeptoMetrix Launches PROtrol: Quality Control Material for the Lateral Flow Immunoassay Market

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

    Related Posts

    Risk-On or Risk-Off? How to Read Global Sentiment Before You Trade

    July 20, 2026

    Bond Yields Are Moving FX More Than Headlines – Here’s Why

    July 13, 2026

    Tamchy Special Financial Investment Territory on Issyk-Kul Launched in Kyrgyzstan

    July 6, 2026
    Latest News

    Moderna begins Ebola vaccine trial amid DR Congo outbreak

    Health August 5, 2026

    The study will operate at three Canadian sites and enroll about 80 healthy adults. Researchers will assess the vaccine’s safety, tolerability and ability to produce an immune response. The trial will not determine whether the vaccine prevents infection because Phase 1 studies focus on early safety data. The Coalition for Epidemic Preparedness Innovations has committed up to $50 million for preclinical work, the trial and production of additional research doses. WHO recorded 3,605 confirmed cases and 1,587 deaths in DR Congo through July 30. At least 651 patients had recovered by that date. Updated figures cited by CEPI on August 4 placed infections above 3,800 and deaths above 1,700. Cases had reached 49 health zones across Ituri, North Kivu, South Kivu, Haut-Uélé and Tshopo provinces. Thirty-three health zones had reported recent infections, while Ituri accounted for 88% of confirmed cases.

    Guatemala raises red alert as Fuego volcano erupts

    August 5, 2026

    OECD inflation eases to 4.2% as lower energy rates take hold

    August 5, 2026

    Oil prices fall as Brent and WTI reach three-week lows again

    August 5, 2026

    Eastern Washington fires leave 700 structures destroyed

    August 4, 2026

    Michigan reports first deaths tied to cyclospora outbreak

    August 4, 2026

    Oil prices swing after Brent tops $90 on supply strains

    August 3, 2026

    Trump cancels Iran strikes pending rapid nuclear deal

    August 3, 2026
    © 2026 Mashreq Daily | All Rights Reserved
    • Home
    • Contact Us

    Type above and press Enter to search. Press Esc to cancel.